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GM1-gangliosidosisβ-galactosidase (GLB1) forms a functional lysosomal multienzyme complex with lysosomal protective
protein (PPCA) and neuraminidase 1 (NEU1) which is important for its intracellular processing and activity.
Mutations in the β-galactosidase gene cause the lysosomal storage disease GM1-gangliosidosis. In order to
identify additional molecular changes associated with the presence of β-galactosidase mutations, the
expression of canine lysosomal multienzyme complex components in GLB1+/+, GLB1+/− and GLB1−/−
ﬁbroblasts was investigated by quantitative RT-PCR, Western blot and enzymatic assays. Quantitative RT-PCR
revealed differential regulation of total β-galactosidase, β-galactosidase variants and protective protein for β-
galactosidase gene (PPGB) in GLB1+/− and GLB1−/− compared to GLB1+/+ ﬁbroblasts. Furthermore, it was
shown that PPGB levels gradually increased with the number of mutant β-galactosidase alleles while no
change in the NEU1 expression was observed. This is the ﬁrst study that simultaneously examine the effect of
GLB1+/+, GLB1+/− and GLB1−/− genotypes on the expression of lysosomal multienzyme complex
components. The ﬁndings reveal a possible adaptive process in GLB1 homozygous mutant and heterozygous
individuals that could facilitate the design of efﬁcient therapeutic strategies.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
From DNA polymorphisms to protein degradation, eukaryotic gene
expression requires chains of complex regulated processes [1]. Due to
either structural defects or abnormal processing, impairments in these
processes may lead to severe disorders. For several Mendelian
diseases, the molecular cause has been successfully identiﬁed [2–4];
however, in the majority of the “simple” genetic disorders, a wide
phenotypic variability in terms of clinical phenotype and disease
severity has been observed [5–7]. Therefore, clinical manifestations of
monogenic disorders seem to be analogous to complex traits [7]. One
reason for this complexity is the regulation of gene expression at
different levels [8,9]. For different genes, certain steps in the regulation
of their expression were described after identiﬁcation of a speciﬁc
clinico-pathological phenotype. Thus, β-galactosidase (GLB1; EC
3.2.1.23) deﬁciencies were associated with the lysosomal storage
disease GM1-gangliosidosis (OMIM # 230500; OMIA # 00402) which
displays threemajor types (types I, II and III) in humanswith respect to
the age of onset and clinico-pathologicalmanifestations [10–12]. Other: +49 0511 9538675.
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ll rights reserved.types of β-galactosidase gene (GLB1) mutationswere also identiﬁed in
Morquio type B disease characterized by ganglioside accumulation
in several organs without central nervous system involvement [13].
Moreover, due to normal alternative splicing, the GLB1 encodes,
additionally to β-galactosidase, the elastin-binding protein (EBP) [14].
As a consequence, structural defects of GLB1 were associated with
impaired elastogenesis [15]. Similar variability of GM1-gangliosidosis
has also been described in dogs where the disease resembles either
type I (English Springer Spaniel) or type II (Alaskan huskies, Shiba
dogs, Portuguese Water Dog, mixed Beagle) human GM1-gangliosido-
sis [16–18]. Furthermore, structural defects affecting the co- and post-
transcriptional processing of GLB1 like pre-mRNA splicing or genera-
tion of premature termination codons (PTC)were identiﬁed in humans
and dogs [19–21]. Other studies showed that abnormal transcripts can
evade the cellular surveillance mechanismwhen the PTC is located on
the last exon [22–24].
After translation, GLB1 forms a functional lysosomal multienzyme
complex (LMC) with neuraminidase (NEU1) and lysosomal protective
protein (PPCA), which is important for its intracellular processing and
activity [25–27]. Defects of either the hydrolytic or the protective
components of LMC lead to abnormal phenotypes with varying
degrees of clinical severity [28]. Moreover, the senescence-associated
GLB1 was identiﬁed as being the normal lysosomal GLB1 whose
Table 1







Sequence Positions Size of PCR
product (bp)
GLB1 97fw 5′-TTC ACA ATT GAC TAC
AGC CAC-3′
79–100 326
DQ 196436 98rev 5′-TAA TAG CCA AGC AGG
TAA TC-3′
384–405
GLB1ΔEx15 Ex14fw 5′-TCT GAA CAT AAC CGG
GAA GG-3′⁎
1390–1409 107
DQ 196436⁎ Ex14/16rev 5′-TCC ACA GAC CCT TAA
AAT C-3′⁎
1475–1488
GLB1dupl Dupl fw 5′-TTG CCC CAG GAT CCC
AGA C-3′⁎
1697–1715 76
DQ 196436⁎ Ex15/16 5′-TAA TCC ACA CCT GAC
CCT TG-3′⁎
1754–1773
PPGB PPGBfw 5′-CCT ATG AGC AGA ATG
ACA ACT CC-3′
687–709 290
NW 876277 PPGBrev 5′-GGC AGG CGA GTG AAG
ATG TT-3′
954–983
NEU1 NEU1fw 5′-CAT GTT GGT GTG GAG
CAA AG-3′
507–526 195
XM 538838 NEU1rev 5′-CAC TGA GGA GGC AGA
AGA CC-3′
681–700
GAPDH GAPDHfw 5′-GCC AAA AGG GTC ATC
ATC TC-3′
340–359 229
AB 038240 GAPDHrev 5′-GGC CAT CCA CAG TCT
TCT-3′
548–565
GLB1 — canine β-galactosidase gene; GLB1ΔEx15 — mutant canine β-galactosidase
lacking exon 15; GLB1dupl—mutant canine β-galactosidase with the abnormal exon 15
carrying the 19 bp duplication; PPGB — protective protein for β-galactosidase gene;
NEU1— neuraminidase 1 gene; GAPDH— glyceraldehyde-3-phosphate-dehydrogenase;
fw=sense; rev=antisense; Ex14=canine GLB1 exon 14; Ex14/16=boundary
between exons 14 and 16 in the mutant canine GLB1 lacking exon 15; dupl=19 bp
duplication in exon 15 of canine GLB1; ⁎ — primers were generated using wild-type (DQ
196436) and mutant speciﬁc GLB1 sequences.
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[29,30].
A 19 bp duplication located in exon 15 of the canine GLB1 gene was
identiﬁed in Alaskan huskies with GM1-gangliosidosis [17,31,32]. This
genetic modiﬁcation either disrupts a potential exonic splicing
enhancer sequence (ESE) leading to the re-framing of the mRNA by
skipping the mutant exon 15 or generates a PTC on the last exon.
Therefore, two GLB1 mRNA populations were identiﬁed in diseased
homozygous mutant dogs: one mRNA isoform lacking the exon 15
(GLB1ΔEx15) and the other one carrying the abnormal exon 15 with
the 19 bp duplication (GLB1dupl) [17,31,32].
For further therapeutic approaches it is important to understand in
which ‘molecular environment’ the therapy will be applied. To deﬁne
this ‘molecular environment’ in a canine model of late infantile GM1-
gangliosidosis, the regulation of the GLB1mRNA expression of normal
and abnormal variants and the GLB1 activity in ﬁbroblasts with
different GLB1 genotypes were investigated.
Furthermore, possible mechanisms on how the GLB1 activity is
maintained at sufﬁcient levels in heterozygous individuals were
analyzed by investigating the relationship between GLB1 expression
and the other LMC components, PPGB and NEU1.
2. Materials and methods
2.1. Cell culture procedures
Primary canine skin ﬁbroblasts from 26 healthy dogs (10
homozygous GLB1+/+ and 14 heterozygous GLB1+/−) and two
diseased homozygous (GLB1−/−) were used [31,33,34]. All experi-
ments were performed with ﬁbroblasts at passage 3.
2.2. RNA extraction, cDNA synthesis and primer design
Total RNA was isolated from primary skin ﬁbroblasts using
the RNeasy Mini Kit (Qiagen, Hilden, Germany) followed by a
DNase treatment (Qiagen, Hilden, Germany) according to the
manufacturer's instructions. The OmniScript™ kit (Qiagen, Hilden,
Germany), oligo dT12 (Roche, Mannheim, Germany) and 500 ng
RNA were used for cDNA synthesis. The primers used for
quantiﬁcation of GLB1, PPGB, NEU1 and glyceraldehyde-3-phos-
phate-dehydrogenase (GAPDH) mRNA expression were designed
using Primer 3 v 0.4.0 software and the published sequences
[(GenBank™ accession no. DQ196436, NW 876277, XM 538838
and AB038240) [35]. The characteristics of these primers are
presented in Table 1.
To distinguish between the different populations of GLB1 mRNAs
(total GLB1, GLB1ΔEx15 and GLB1dupl) speciﬁc primer pairs were
designed as shown in Fig. 1.
2.3. Quantitative RT-PCR (qRT-PCR)
Quantitative RT-PCRs were performed with an Mx3005P™
Instrument (Stratagene, La Jolla, CA, USA) in a total volume of
25 μl. For each reaction, 1 μl cDNA was placed in a 24 μl reaction
mixture containing: 0.25 μl Taq DNA Polymerase (5 U/μl) (Invitrogen,
Karlsruhe, Germany), 2.5 μl supplied 10×buffer, 1.25 μl MgCl2
(50 mM), 0.5 μl dNTP (10 mM) (Invitrogen, Karlsruhe, Germany)
and 0.5 μl of each primer (10 μM) diluted in distilled water. SYBR®
Green I was used as DNA-binding dye while ROX was chosen as
reference dye. The cycling temperature proﬁle was identical for all
transcripts and consisted of: 95 °C for 5 min followed by 40 cycles of
denaturation at 95 °C for 30 s, annealing at 68 °C for 1 min and
extension at 72 °C for 30 s. Melting curves were generated at the end
of each ampliﬁcation reaction.
To generate gene speciﬁc standard curves, the PCR products were
run on a 2% agarose gel, excised and eluted using the QIAquick GelExtraction™ kit (Qiagen, Hilden, Germany). The DNA concentration
was measured at 260 nm using the GeneQuant Pro™ RNA/DNA
calculator (GE Healthcare, Freiburg, Germany). The identity of each
amplicon was conﬁrmed by sequencing (Agowa GmbH, Berlin,
Germany). All reactions were performed in quadruplicate.
2.4. Quantiﬁcation of mRNA expression levels
Each assay included two standard curves (one for the gene of
interest and one for GAPDH) using serial 10-fold dilutions (ranging
from E+08 to E+02 copies). The correlation coefﬁcient (R2) of the
standard curves was above 0.985. The slopes of the standard curves
were used to determine the reaction efﬁciency (e) using the
equation: (e)=10(−1/slope)−1 [32]. Thus, obtained ampliﬁcation
efﬁciencies were above 95%. Between quadruplicates, the median
coefﬁcient of variation (CV) was calculated as CV=SD/mean and
was under 5%. Due to differences in the amplicon sizes, the CT-values
were corrected for PCR efﬁciency (e) using the following formula:
CTe=100%=CTe [log(1+e)/ log(2)]. The relative number of mole-
cules for each transcript was determined by interpolating the
CTe=100% values of the gene of interest (GOI) to each standard
curve and the obtained values were normalized with respect to
GAPDH for each individual cDNA. The relative expression level was
calculated by the 2−ΔΔCt method using the expression from GLB1+/+
ﬁbroblasts as calibrator [36–38]. Statistical differences between
groups were assessed by t-test and differences with pb0.05 were
considered signiﬁcant.
2.5. β-galactosidase enzymatic assays
GLB1 activities were measured as previously described [18,33,34]
and expressed in mU/mg protein.
Fig. 3. Expression of total GLB1 mRNA in GLB1+/+, GLB1+/−, GLB1−/− ﬁbroblasts.
GLB1+/+, GLB1+/−, GLB1−/− correspond to GLB1 mRNA expression levels in
homozygous dominant (GLB1+/+), heterozygous (GLB1+/−) and homozygous reces-
sive (GLB1−/−) ﬁbroblasts. Columns show relative expression levels of GLB1 normal-
ized to canine GAPDH analyzed by quantitative RT-PCR. Statistically signiﬁcant
differences (⁎ — pb0.05) were observed between GLB1 mRNA levels of GLB1+/+
compared to GLB1+/− and GLB1−/− ﬁbroblasts.
Fig. 1. Design of the primer pairs used to detect different populations of GLB1 mRNA.
Ex14=canine GLB1 exon 14; Ex15=canine GLB1 exon 15; Ex16=canine GLB1 exon 16;
fw=sense; rev=antisense primers; GLB1=wild-type canine GLB1; GLB1ΔEx15=
mutant canine GLB1 lacking exon 15; GLB1dupl=mutant canine GLB1 with the
abnormal exon 15 carrying the 19 bp duplication. Different populations of GLB1mRNA:
total GLB1, GLB1ΔEx15 and GLB1dupl were speciﬁcally detected by using GLB1fw-
GLB1rev, Ex14fw-Ex14/16rev and Duplfw-Ex15/16rev primers.
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Proteins were extracted and subjected to SDS-PAGE analysis as
described [39]. For detection of PPCA (precursor — 54 kD and mature
form — 32 and 20 kD) and actin, the polyclonal anti-PPCA (Acris
GmbH, Hiddenhausen, Germany) and anti-actin antibody (Santa Cruz
Biotechnology, Heidelberg, Germany) were used as primary anti-
bodies. As secondary antibodies the anti-rabbit IgG, HRP-linked
antibody (Santa Cruz Biotechnology, Hiddenhausen, Germany) and
the polyclonal rabbit anti-mouse IgG HRP-linked antibody (Dako
GmbH, Hamburg, Germany) were utilized. All antibodies were diluted
1:1000. The antigen-antibody complexes were visualized with the ECL
chemiluminescence system (Amersham) and exposed to a Kodak X-
OMAT ﬁlm. Each set of samples (homozygous GLB1+/+, heterozygous
GLB1+/− and homozygous GLB1−/−) was measured in three inde-
pendent experiments. The densitometric analysis of the resulted
protein bands was performed using the Scion Image Beta Software
(Scion Corp., Frederick, MD, USA). The integrated optic densities were
normalized to actin and the statistical differences between groups
were assessed by t-test and differences with pb0.05 were considered
signiﬁcant.
3. Results
3.1. GLB1 activities in GLB1+/+, GLB1+/− and GLB1−/− ﬁbroblasts
GLB1+/+ and GLB1+/− ﬁbroblasts showed high levels of GLB1
activities whereas GLB1−/− cells had a signiﬁcant deﬁciency in theFig. 2. GLB1 activity in GLB1+/+, GLB1+/−, GLB1−/− ﬁbroblasts. GLB1+/+, GLB1+/−,
GLB1−/− correspond to GLB1 activities in homozygous dominant (GLB1+/+), hetero-
zygous (GLB1+/−) and homozygous recessive (GLB1−/−) ﬁbroblasts. GLB1 activities are
given as mU/mg protein. The GLB1 activity in GLB1−/− ﬁbroblasts represented 2.73%
(10±1.43 mU/mg) of those of GLB1+/+ and GLB1+/− [365.1±122.33 and 340±
127.87 mU/mg respectively; ⁎ — statistically signiﬁcant differences (pb0.05)].enzymatic activity of GLB1 (Fig. 2). Surprisingly, no signiﬁcant
difference was observed between the GLB1 activities of GLB1+/+
and GLB1+/− ﬁbroblasts.
3.2. mRNA levels of total GLB1 in GLB1+/+, GLB1+/− and GLB1−/−
ﬁbroblasts
To further investigate how GLB1 activity is maintained at similar
levels in GLB1+/+ and GLB1+/− ﬁbroblasts, GLB1 mRNA expression
was analyzed by qRT-PCRs using a universal GLB1 primer pair (GLB1fw
and GLB1rev). These primers were designed to detect the total GLB1
mRNA expression represented by one (GLB1wild-type)mRNA popula-
tion in GLB1+/+ ﬁbroblasts, three (GLB1wild-type, GLB1ΔEx15 and
GLB1dupl) in GLB1+/− and two (GLB1ΔEx15 and GLB1dupl) mRNA
populations in GLB1−/− ﬁbroblasts (Fig. 1). Relative quantiﬁcation
revealed the GLB1 mRNA expression pattern in GLB1+/+, GLB1+/−,
GLB1−/− genotypes (Fig. 3) with a signiﬁcant increase in total GLB1
mRNA expression in heterozygous and homozygous recessive ﬁbro-
blasts. Thus, in GLB1+/− and GLB1−/− ﬁbroblasts total GLB1 mRNA
expression showed a 2.68 and 1.85- up-regulation respectively
compared to GLB1+/+ ﬁbroblasts.
3.3. mRNA levels of GLB1 variants in GLB1+/+, GLB1+/− and GLB1−/−
ﬁbroblasts
To determine which GLB1 population contributed to the high
levels of GLB1 mRNA in GLB1+/− ﬁbroblasts and to analyze possible
alterations in the alternative splicing process between GLB1+/− and
GLB1−/− ﬁbroblasts, the expression of GLB1 variants (GLB1ΔEx15 and
GLB1dupl) was further investigated. While, as expected, the GLB1+/+
cells showed no GLB1ΔEx15 mRNA expression, the GLB1−/−Fig. 4. Expression of GLB1ΔEx15 mRNA (lacking exon 15) in GLB1+/− and GLB1−/−
ﬁbroblasts. GLB1+/− and GLB1−/− correspond to GLB1ΔEx15 mRNA expression values
in heterozygous (GLB1+/−) and homozygous recessive (GLB1−/−) ﬁbroblasts. Columns
show relative expression levels of GLB1ΔEx15 normalized to canine GAPDH analyzed by
quantitative RT-PCR. Statistically signiﬁcant differences (⁎ — pb0.05) of GLB1ΔEx15
mRNA were observed between GLB1+/− and GLB1−/− ﬁbroblasts.
Fig. 5. Expression of GLB1duplmRNA (with the exon 15 carrying the 19 bp duplication) in
GLB1+/−, GLB1−/− ﬁbroblasts. GLB1+/− and GLB1−/− correspond to GLB1dupl mRNA
expression levels in heterozygous (GLB1+/−) and homozygous recessive (GLB1−/−)
ﬁbroblasts. Columns show relative expression levels of GLB1dupl normalized to canine
GAPDH analyzed by quantitative RT-PCR. No signiﬁcant differences (pb0.05) in the
expression levels of GLB1dupl mRNA in GLB1+/− and GLB1−/− cells were observed.
Fig. 7. Expression of PPGBmRNA inGLB1+/+,GLB1+/− andGLB1−/− ﬁbroblasts.GLB1+/+,
GLB1+/−, GLB1−/− correspond to PPGBmRNA expression levels in homozygous dominant
(GLB1+/+), heterozygous (GLB1+/−) and homozygous recessive (GLB1−/−) ﬁbroblasts.
Columns show relative expression levels of PPGB mRNA normalized to canine GAPDH
analyzed by quantitative RT-PCR. Statistically signiﬁcant differences (⁎ — pb0.05) were
observed between PPGBmRNA levels from GLB1+/+ compared to GLB1+/− and GLB1−/−
ﬁbroblasts.
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compared to GLB1+/− cells (Fig. 4). For the GLB1dupl mRNA
population, the expression increased slightly in GLB1−/− ﬁbroblasts
compared to GLB1+/− ﬁbroblasts but was not statistically signiﬁcant
(Fig. 5). Analysis of the absolute GLB1ΔEx15 and GLB1dupl mRNA
levels revealed that the GLB1dupl mRNA exceeded the expression of
GLB1ΔEx15 mRNA by 10-fold (E+04/E+03). Due to great simila-
rities between GLB1wild-type and GLB1dupl sequences, a speciﬁc
quantiﬁcation of GLB1wild-type transcript was not possible. More-
over, eventual interference between GLB1 and EBP expression was
excluded while a canine EBP expression was not detected using
primers for the canine GLB1 similar with those used to amplify the
alternatively spliced variant of the human GLB1 named the human
EBP (data not shown).
3.4. mRNA levels of NEU1 in GLB1+/+, GLB1+/− and GLB1−/−
ﬁbroblasts
To further investigate whether this increase in total GLB1 mRNA
expression in GLB1+/− ﬁbroblasts was associated with modiﬁcations
in the expression of NEU1, additional qRT-PCRs were performed. The
NEU1 mRNA levels in GLB1+/− and GLB1−/− ﬁbroblasts were not
signiﬁcantly altered compared to GLB1+/+ ﬁbroblasts (Fig. 6).
3.5. mRNA and protein levels of PPGB in GLB1+/+, GLB1+/− and GLB1−/−
ﬁbroblasts
The investigation of the PPGB mRNA expression revealed a
gradually increased expression in GLB1+/+, GLB1+/− and GLB1−/−
ﬁbroblasts with the highest expression in GLB1−/− (4.57-fold),
intermediate expression in GLB1+/− (2.06) and the lowest expression
in GLB1+/+ ﬁbroblasts (Fig. 7). At the protein level, PPCA precursorFig. 6. Expression of NEU1mRNA in GLB1+/+, GLB1+/− and GLB1−/− ﬁbroblasts. GLB1+/+,
GLB1+/−, GLB1−/− correspond to NEU1 mRNA expression levels in homozygous dominant
(GLB1+/+), heterozygous (GLB1+/−) and homozygous recessive (GLB1−/−) ﬁbroblasts.
Columns show relative expression levels of NEU1 normalized to canine GAPDH analyzed by
quantitative RT-PCR. No signiﬁcant differences (pb0.05) in the expression levels of NEU1
mRNA in GLB1+/+, GLB1+/− and GLB1−/− cells were observed.(54 kD) showed a similar pattern of expression as PPGBmRNA (Fig. 8).
Densitometric analysis of the Western blot bands revealed a
statistically signiﬁcant increase in PPCA precursor expression in
GLB1−/− (1.14±0.21) compared to GLB1+/+ ﬁbroblasts (0.11±
0.01). In contrast to PPCA precursor, the mature forms of PPCA (32
and 20 kD bands) were not present in all samples and their
appearance did not correlate with the GLB1 genotypes.
4. Discussion
Over the years, the genetic defects causing several Mendelian
disorders have been elucidated and it was shown that different
mutations can affect the expression of a single gene at multiple
levels. Moreover, single genes are involved in various biological
processes. Thus, the phenotypical manifestations of a so-called
“simple” genetic defect display variability similar to complex traits.
Therefore, even for monogenic diseases, the identiﬁcation of the
molecular cause is only the ﬁrst step in designing further therapeutic
approaches [40].
In the present study, the expression of GLB1, PPGB and NEU1 in
GLB1+/+, GLB1+/− and GLB1−/− genotypes was comparatively
analyzed, to investigate additional molecular changes associated
with the presence of GLB1 mutations. The identiﬁcation and
characterization of such modiﬁcations are essential for the develop-
ment of efﬁcient type-speciﬁc therapeutic strategies for the treatment
of GM1-gangliosidosis.
The majority of lysosomal genes vary substantially in their
expression [41]. Thereby, modiﬁcations of the GLB1mRNA expression
under particular conditions cannot be excluded. Differential expres-
sion of GLB1 was investigated by comparing healthy individuals and
patients suffering from GM1-gangliosidosis. However, as for other
monogenic diseases, investigating heterozygous GLB1+/− individuals
is important not only for the detection of mutant allele carriers but
also for developing strategies to antagonize the effect of the mutant
allele.
In the present study, the GLB1 activity of GLB1+/+, GLB1+/− and
GLB1−/− ﬁbroblastswas analyzed and, as expected, it was observed that
GLB1−/− ﬁbroblasts have a severe deﬁciency in GLB1 activity compared
to GLB1+/+ and GLB1+/− ﬁbroblasts. Interestingly, no signiﬁcant
differences between ﬁbroblasts carrying one or two wild-type alleles
were identiﬁed, suggesting a differential regulation of GLB1 activity in
these genotypes. To further elucidate this observation, the total GLB1
mRNA expression was investigated. In GLB1+/− compared to GLB1+/+
ﬁbroblasts a 2.68-fold increase of total GLB1 mRNA expression was
shown. Thus, GLB1 alleles elevated their expression as a result of a
mutation in theGLB1 gene. In addition,GLB1mRNAexpressionwas 1.85-
fold increased in GLB1−/−. This observation is in contrast to previous
reports which showed no difference between the GLB1 expression in
Fig. 8. Expression of PPCA protein in GLB1+/+, GLB1+/− and GLB1−/− ﬁbroblasts. GLB1+/+, GLB1+/−, GLB1−/− correspond to PPCA protein levels in homozygous dominant (GLB1+/+),
heterozygous (GLB1+/−) and homozygous recessive (GLB1−/−) ﬁbroblasts normalized to actin protein. Statistically signiﬁcant differences (⁎ — pb0.05) were observed between the PPCA
protein of GLB1−/− compared to GLB1+/−and GLB1+/+ ﬁbroblasts.
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levels of total GLB1 mRNA in GLB1+/− compared to GLB1+/+ could also
result from an increased expression of each GLB1 transcript. The great
similarities betweenGLB1wild-type and theGLB1dupl sequences (wild-
type: 5′- ggatcccagacttgccccaggacacc-3′; GLB1dupl: 5′-ggatccca-
gacttgccccagga tcccagacttgccccaggacacc-3′) did not allow a direct
differentiation between these two transcripts. In order to overcome
these difﬁculties the mean β-galactosidase activity was compared
between GLB1+/+ and GLB1+/− individuals, however no signiﬁcant
differences were found (pb0.05). Furthermore, GLB1+/+ individuals
carry two wild-type alleles which are responsible for the measured β-
galactosidase activity (mean value of 365.1±122.33 mU/mg), while
GLB1+/− individuals possess only one normal allele which results in a
similarmeanvalueofβ-galactosidase activity (340±127.87mU/mg). In
addition, only GLB1wild-type mRNA gives rise to an active protein [18].
Thus, itwas concluded that thewild-type allelewill have higher levels of
transcription in GLB1+/− individuals in order to maintain the β-
galactosidase activity at levels similar to those detected in GLB1+/+
individuals. Moreover, human GM1-gangliosidosis patients carrying
splicing defects displayed a decrease in total GLB1 mRNA expression
[4]. As previously mentioned, the 19 bp duplication in canine GM1-
gangliosidosis generates a PTCwhich should trigger nonsensemediated
decay (NMD) of the abnormal mRNA. However, due to its special
position (less than 50–55 nucleotides upstream the 3′-most exon–exon
junction), this PTC confers ‘resistance’ against NMD [22,24,43]. As a
sequel, the mRNA abundance in such NMD-resistant mRNA carriers
differs from those lacking these RNAs. This could explain why the GLB1
mRNA levels were higher in GLB1−/− ﬁbroblasts compared to GLB1+/+
Alaskan husky ﬁbroblasts. To prove the presence of NMD-resistant
mRNA and to further investigate the distributions of both GLB1 variants
in GLB1+/− and GLB1−/− ﬁbroblasts, qRT-PCR using variant-speciﬁc
primers was performed. Thus, NMD-resistant mRNA (GLB1dupl) was
detected inGLB1+/− andGLB1−/− ﬁbroblasts. In addition, after absolute
RT-PCR quantiﬁcation, it was observed that only a small fraction of this
mRNA lacks themutant exon 15 (GLB1ΔEx15). The amino acid sequence
encoded by exon 15 contains a cleavage site important for the correct
lysosomal processing of GLB1.
The GLB1 enzymatic activity depends on its correct assembly with
PPCA and NEU1 to form the lysosomal multienzyme complex[26,44,45]. Albeit the elevated levels of GLB1 expression in GLB1+/−
ﬁbroblasts a lack of an appropriate amount of the other LMC
components could potentially lead to deﬁciencies in GLB1 activity.
Therefore we further investigated the expression of the PPGB and
NEU1 genes in GLB1+/+, GLB1+/− and GLB1+/− ﬁbroblasts. Thus,
after analysis of NEU1 mRNA levels in these ﬁbroblasts no signiﬁcant
difference was observed between GLB1+/+, GLB1+/− and GLB1−/−
cells. Furthermore, our previous analyses of the NEU1 enzymatic
activity of canine ﬁbroblasts from healthy, carriers and homozygous
Alaskan huskies showed no differences among the three genotypes
[33]. These results are in concordance with the observation that some
human GLB1 mutant alleles are not associated with modiﬁcations in
NEU1 expression [10]. A lack of variation in the NEU1 expression
was also described when sialidosis patients (NEU1−/−) were
compared to control healthy individuals (NEU1+/+) [46].
Housekeeping gene characteristics were initially reported for the
PPGB promoter; however, the distribution pattern of PPGB requires a
speciﬁc regulation that cannot be anticipated by the housekeeping
gene properties of its promoter [39,47]. In the present study, a
differential expression of PPGB mRNA was observed in GLB1+/+,
GLB1+/− and GLB1−/− ﬁbroblasts. This correlates with the increase
of total GLB1 mRNA level in GLB1+/− and GLB1−/− ﬁbroblasts
compared to GLB1+/+ cells.
Previous studies described two distinct and separate functions of
the PPCA: the carboxypeptidase function as mature form and the
protective role as precursor [48]. In our experiments, the expression of
the PPCA precursor correlates with GLB1 genotypes (low in GLB1+/+,
medium in GLB1+/− and high in GLB1−/−) while the mature forms
showed not only a GLB1mutation type-dependent expression [10] but
also individual variations. These observations suggest a role of PPCA
precursor in GLB1 protection in GLB1+/− and GLB1−/− ﬁbroblasts.
Therefore, the GLB1 activity in GLB1+/− ﬁbroblasts seems to be
maintained at high levels by a simultaneous increase of GLB1 and
PPCA precursor expression. Interestingly, the observation that PPCA
precursor expression in GLB1−/− ﬁbroblasts was signiﬁcantly higher
compared to GLB1+/− ﬁbroblasts, indicates amechanismwhereby the
PPCA precursor level is increased in order to antagonize the lack of
GLB1 activity. Further studies are necessary to decipher this mechan-
ism and its clinical relevance.
987R. Kreutzer et al. / Biochimica et Biophysica Acta 1792 (2009) 982–987Acknowledgements
The present work was supported by a research grant from the
German Research Council (DFG Grant BA815/7-1 and BA815/7-2).
References
[1] L. Stalder, O. Mühlemann, The meaning of nonsense, Trends Cell Biol. 18 (2008)
315–321.
[2] Z.H. Wang, B. Zeng, H. Shibuya, G.S. Johnson, J. Alroy, G.M. Pastores, S. Raghavan,
E.H. Kolodny, Isolation and characterization of the normal canine beta-galacto-
sidase gene and its mutation in a dog model of GM1-gangliosidosis, J. Inherit.
Metab. Dis. 23 (2000) 593–606.
[3] O. Yamato, D. Endoh, A. Kobayashi, Y. Masuoka, M. Yonemura, A. Hatakeyama, H.
Satoh, M. Tajima, M. Yamasaki, Y. Maede, A novel mutation in the gene for canine
acid beta-galactosidase that causes GM1-gangliosidosis in Shiba dogs, Inherit.
Metab. Dis. 25 (2002) 525–526.
[4] A. Caciotti, M.A. Donati, E. Procopio, M. Filocamo, W. Kleijer, W. Wuyts, B.
Blaumeiser, A. d'Azzo, L. Simi, C. Orlando, F. McKenzie, A. Fiumara, E. Zammarchi,
A. Morrone, GM1 gangliosidosis: molecular analysis of nine patients and
development of an RT-PCR assay for GLB1 gene expression proﬁling, Hum.
Mutat. 28 (2007) 204.
[5] D.J. Weatherall, Phenotype–genotype relationships in monogenic disease: lessons
from the thalassaemias, Nat. Rev. Genet. 2 (2001) 245–255.
[6] G.R. Cutting, Modiﬁer genetics: cystic ﬁbrosis, Annu. Rev. Genomics Hum. Genet.
2005 (6) (2005) 237–260.
[7] S. Rossetti, P.C. Harris, Genotype–phenotype correlations in autosomal dominant
and autosomal recessive polycystic kidney disease, Am. Soc. Nephrol. 18 (2007)
1374–1380.
[8] F.J. Iborra, A.E. Escargueil, K.Y. Kwek, A. Akoulitchev, P.R. Cook, Molecular cross-
talk between the transcription, translation, and nonsense-mediated decay
machineries, J. Cell Sci. 117 (2004) 899–906.
[9] A.B. Shyu, M.F. Wilkinson, A. van Hoof, Messenger RNA regulation: to translate or
to degrade, EMBO J. 27 (2008) 471–481.
[10] R. Santamaria, A. Chabás, J.W. Callahan, D. Grinberg, L. Vilageliu, Expression and
characterization of 14 GLB1 mutant alleles found in GM1-gangliosidosis and
Morquio B patients, J. Lipid Res. 48 (2007) 2275–2282.
[11] N. Brunetti-Pierri, F. Scaglia, GM(1) gangliosidosis: review of clinical, molecular,
and therapeutic aspects, Mol. Genet. Metab. 94 (2008) 391–396.
[12] R. Santamaria, M. Blanco, A. Chabás, D. Grinberg, L. Vilageliu, Identiﬁcation of 14
novel GLB1 mutations, including ﬁve deletions, in 19 patients with GM1
gangliosidosis from South America, Clin. Genet. 71 (2007) 273–279.
[13] J.E. Trojak, C.K. Ho, R.A. Roesel, L.S. Levin, S.E. Kopits, G.H. Thomas, S. Toma,
Morquio-like syndrome (MPS IV B) associated with deﬁciency of a beta-
galactosidase, Johns Hopkins Med. J. 146 (1980) 75–79.
[14] A. Hinek, M. Rabinovitch, F. Keeley, Y. Okamura-Oho, J. Callahan, The 67-kD
elastin/laminin-binding protein is related to an enzymatically inactive,
alternatively spliced form of beta-galactosidase, J. Clin. Invest. 91 (1993)
1198–1205.
[15] A. Caciotti, M.A. Donati, A. Boneh, A. d'Azzo, A. Federico, R. Parini, D. Antuzzi, T.
Bardelli, D. Nosi, V. Kimonis, E. Zammarchi, A. Morrone, Role of beta-galactosidase
and elastin binding protein in lysosomal and nonlysosomal complexes of patients
with GM1-gangliosidosis, Hum. Mutat. 25 (2005) 285–292.
[16] O. Yamato, Y. Masuoka, M. Yonemura, A. Hatakeyama, H. Satoh, A. Kobayashi, M.
Nakayama, T. Asano, T. Shoda, M. Yamasaki, K. Ochiai, T. Umemura, Y. Maede,
Clinical and clinico-pathologic characteristics of Shiba dogs with a deﬁciency of
lysosomal acid beta-galactosidase: a canine model of human GM1 gangliosidosis,
J. Vet. Med. Sci. 65 (2003) 213–217.
[17] R. Kreutzer, T. Leeb, G MüllerA , MoritzW , BaumgärtnerA , duplication in the
canine beta-galactosidase gene GLB1 causes exon skipping and GM1-gang-
liosidosis in Alaskan huskies, Genetics 170 (2005) 1857–1861.
[18] R. Kreutzer, M. Kreutzer, M.J. Pröpsting, A.C. Sewell, T. Leeb, H.Y. Naim, W.
Baumgärtner, Insights into post-translational processing of beta-galactosidase in
an animal model resembling late infantile human G-gangliosidosis, J. Cell. Mol.
Med. 12 (2008) 1661–1671.
[19] Y. Suzuki, H. Sakuraba, A. Oshima, K. Yoshida, M. Shimmoto, T. Takano, Y. Fukuhara,
Clinical and molecular heterogeneity in hereditary beta-galactosidase deﬁciency,
Dev. Neurosci. 13 (1991) 299–303.
[20] K. Yoshida, A. Oshima, H. Sakuraba, T. Nakano, N. Yanagisawa, K. Inui, S. Okada, E.
Uyama, R. Namba, K. Kondo, GM1 gangliosidosis in adults: clinical and molecular
analysis of 16 Japanese patients, Ann. Neurol. 31 (1992) 328–332.
[21] R. Santamaria, A. Chabás, M.J. Coll, C.S. Miranda, L. Vilageliu, D. Grinberg, Twenty-
one novel mutations in the GLB1 gene identiﬁed in a large group of GM1-
gangliosidosis and Morquio B patients: possible common origin for the prevalent
p.R59H mutation among gypsies, Hum. Mutat. 27 (2006) 1060.
[22] E. Nagy, L.E. Maquat, A rule for termination-codon position within intron-
containing genes: when nonsense affects RNA abundance, Trends Biochem. Sci. 23
(1998) 198–199.
[23] R. Asselta, S. Duga, S. Spena, E. Santagostino, F. Peyvandi, G. Piseddu, R. Targhetta,
M. Malcovati, P.M. Mannucci, M.L. Tenchini, Congenital aﬁbrinogenemia: muta-
tions leading to premature termination codons in ﬁbrinogen A alpha-chain geneare not associated with the decay of the mutant mRNAs, Blood 98 (2001)
3685–3692.
[24] S. Lualdi, M.G. Pittis, S. Regis, R. Parini, A.E. Allegri, F. Furlan, B. Bembi, M. Filocamo,
Multiple cryptic splice sites can be activated by IDS point mutations generating
misspliced transcripts, J. Mol. Med. 84 (2006) 692–700.
[25] A.V. Pshezhetsky, M. Potier, Stoichiometry of the human lysosomal carboxypepti-
dase-beta-galactosidase complex, Biochem. Biophys. Res. Commun. 195 (1993)
354–362.
[26] A.V. Pshezhetsky, M. Potier, Association of N-acetylgalactosamine-6-sulfate
sulfatase with the multienzyme lysosomal complex of beta-galactosidase,
cathepsin A, and neuraminidase. Possible implication for intralysosomal catabo-
lism of keratan sulfate, J. Biol. Chem. 271 (1996) 28359–28365.
[27] A.V. Pshezhetsky, M. Ashmarina, Lysosomal multienzyme complex: biochemistry,
genetics, and molecular pathophysiology, Prog. Nucleic Acid Res. Mol. Biol. 69
(2001) 81–114.
[28] M. Hiraiwa, Cathepsin A/protective protein: an unusual lysosomal multifunctional
protein, Cell. Mol. Life Sci. 56 (1999) 894–907.
[29] G.P. Dimri, X. Lee, G. Basile, G.M. Acosta, G. Scott, C. Roskelley, E.E. Medrano, M.
Linskens, I. Rubelj, O. Pereira-Smith, M. Peacocke, J. Campisi, A biomarker that
identiﬁes senescent human cells in culture and in aging skin in vivo, Proc. Natl.
Acad. Sci. U. S. A. 92 (1995) 9363–9367.
[30] B.Y. Lee, J.A. Han, J.S. Im, A. Morrone, K. Johung, E.C. Goodwin, W.J. Kleijer, D.
DiMaio, E.S. Hwang, Senescence-associated beta-galactosidase is lysosomal beta-
galactosidase, Aging Cell 5 (2006) 187–195.
[31] R. Kreutzer, G. Müller, T. Leeb, B. Brenig, A. Moritz, W. Baumgärtner, Genetic
testing for GM1-gangliosidosis in the Alaskan Husky, Tierärztl. Prax. 35 (K) (2007)
193–199.
[32] R. Kreutzer, M. Kreutzer, T. Leeb, W. Baumgärtner, Rapid and accurate GM1-
gangliosidosis diagnosis using a parentage testing microsatellite, Mol. Cell. Probes
22 (2008) 252–254.
[33] G. Müller, W. Baumgärtner, A. Moritz, A. Sewell, B. Kustermann-Kuhn,
Biochemical ﬁndings in a breeding colony of Alaskan Huskies suffering from
GM1-gangliosidosis, J. Inherit. Metab. Dis. 21 (1998) 430–431.
[34] G. Müller, S. Alldinger, A. Moritz, A. Zurbriggen, N. Kirchhof, A. Sewell, W.
Baumgärtner, GM1-gangliosidosis in Alaskan huskies: clinical and pathologic
ﬁndings, Vet. Pathol. 38 (2001) 281–290.
[35] S. Rozen, H. Skaletsky, Primer3 on the WWW for general users and for biologist
programmers, Methods Mol. Biol. 132 (2000) 365–386.
[36] C. Pérez, J. Vandesompele, I. Vandenbroucke, G. Holtappels, F. Speleman, P.
Gevaert, P. Van Cauwenberge, C. Bachert, Quantitative real time polymerase chain
reaction for measurement of human interleukin-5 receptor alpha spliced isoforms
mRNA, BMC Biotechnol. 3 (2003) 17.
[37] C. Drögemüller, A. Giese, F. Martins-Wess, S. Wiedemann, L. Andersson, B. Brenig,
R. Fries, T. Leeb, The mutation causing the black-and-tan pigmentation phenotype
of Mangalitza pigs maps to the porcine ASIP locus but does not affect its coding
sequence, Mamm. Genome 17 (2006) 58–66.
[38] A. Ståhlberg, K. Elbing, J.M. Andrade-Garda, B. Sjögreen, A. Forootan, M. Kubista,
Multiway real-timePCR, gene expression proﬁling in yeast Saccharomyces
cerevisiae reveals altered transcriptional response of ADH-genes to glucose
stimuli, BMC Genomics 9 (2008) 170.
[39] E. Ponce, D.P. Witte, R. Hirschhorn, M.L. Huie, G.A. Grabowski, Murine acid alpha-
glucosidase: cell-speciﬁc mRNA differential expression during development and
maturation, Am. J. Pathol. 154 (1999) 1089–1096.
[40] T.A. Burrow, R.J. Hopkin, N.D. Leslie, B.T. Tinkle, G.A. Grabowski, Enzyme
reconstitution/replacement therapy for lysosomal storage diseases, Curr. Opin.
Pediatr. 19 (2007) 628–635.
[41] A.H. Erickson, J.P. Bocock, Targeting to lysosomes in mammalian cells: the
biosynthetic and endocytic pathways, Methods Mol Biol. 390 (2007) 339–361.
[42] D.R. Martin, B.A. Rigat, P. Foureman, G.S. Varadarajan, M. Hwang, B.K. Krum, b.F.
Smith, J.W. Callahan, D.J. Mahuran, H.J. Baker, Molecular consequences of the
pathogenic mutation in feline GM1 gangliosidosis, Mol. Genet. Metab. 94 (2008)
212–221.
[43] O. Isken, Y.K. Kim, N. Hosoda, G.L. Mayeur, J.W. Hershey, L.E. Maquat, Upf1
phosphorylation triggers translational repression during nonsense-mediated
mRNA decay, Cell 133 (2008) 314–327.
[44] M. Potier, L. Michaud, J. Tranchemontagne, L. Thauvette, Structure of the lysosomal
neuraminidase-beta-galactosidase-carboxypeptidase multienzymic complex,
Biochem. J. 267 (1990) 197–202.
[45] H. Ostrowska, K. Krukowska, J. Kalinowska, M. Orłowska, I. Lengiewicz, Lysosomal
high molecular weight multienzyme complex, Cell. Mol. Biol. Lett. 2003 (8)
(2003) 19–24.
[46] C. Sergi, R. Penzel, J. Uhl, S. Zoubaa, H. Dietrich, N. Decker, P. Rieger, J. Kopitz, H.F.
Otto, M. Kiessling, M. Cantz, Prenatal diagnosis and fetal pathology in a Turkish
family harboring a novel nonsense mutation in the lysosomal alpha-N-acetyl-
neuraminidase (sialidase) gene, Hum. Genet. 109 (2001) 421–428.
[47] R.J. Rottier, C.N. Hahn, L.W. Mann, M. del Pilar Martin, R.J. Smeyne, K. Suzuki, A.
d'Azzo, Lack of PPCA expression only partially coincides with lysosomal storage in
galactosialidosis mice: indirect evidence for spatial requirement of the catalytic
rather than the protective function of PPCA, Hum. Mol. Genet. 7 (1998)
1787–1794.
[48] R.M. D'Agrosa, M. Hubbes, S. Zhang, R. Shankaran, J.W. Callahan, Characteristics of
the beta-galactosidase-carboxypeptidase complex in GM1-gangliosidosis and
beta-galactosialidosis ﬁbroblasts, Biochem J. 285 (1992) 833–838.
